IVIS LUMINA II XR FOR OPTICAL IMAGING OF RADIOPHARMACEUTICALS

用于放射性药物光学成像的 IVIS Lumina II XR

• 批准号: 8052174
• 负责人: YUAN-CHUAN TAI
• 金额: $ 21.76万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8052174
• 关键词: Address; Biological; Biological Sciences; Bioluminescence; Categories; Charge; Communities; Development; Ensure; Faculty; Fluorescence; Funding; Generations; Growth; Image; Imaging Device; Imaging technology; Implant; Laboratory Research; Light; Monitor; Mus; Optics; Positron; Positron-Emission Tomography; Process; Radiation; Radiopharmaceuticals; Reporter; Research; Research Personnel; Resolution; Resources; Science; Signal Transduction; Speed; System; Targeted Radiotherapy; Technology; Travel; United States National Institutes of Health; Universities; Washington; design; fluorescence imaging; imaging modality; in vivo; instrument; instrumentation; luminescence; molecular imaging; multimodality; novel; optical imaging; particle; public health relevance; research study; subcutaneous; tumor; ultraviolet

DESCRIPTION (provided by applicant): Throughout the last decade, the use of bioluminescence reporter systems has seen an exponential growth in research applications. As a result, bioluminescence imaging (BLI) has become an indispensible component of molecular imaging at Washington University and throughout the world. The use of multiple imaging modalities to address biological questions is now commonplace in imaging research laboratories. In a new twist on BLI, Robertson et al. (Phys Med Biol 2009) showed that the IVIS 100 and 200 BLI scanners (which have now been replaced by the IVIS Lumina and Spectrum, respectively) could consistently detect a Cerenkov light signal from 18F and 13N nuclides. Cerenkov radiation is produced when a charged particle travels with a velocity that exceeds the speed of light through an insulating medium. Cerenkov radiation is produced in a continuous spectrum from the near ultraviolet through the visible spectrum, distributed inversely proportional to the squire of the wavelength. "Cerenkov luminescence imaging" (CLI) was described for in vivo imaging of mice with radiopharmaceuticals that emit either positron or beta minus, and demonstrated a good correlation with 18FDG PET in detecting a subcutaneous tumor implant. Independently, another group of researchers (Liu et al, PLoS One 2010) validated CLI with additional positron and beta minus emitters. We propose the purchase of an IVIS Lumina II XR (Caliper Life Sciences, Inc.), a new generation molecular imaging tool capable of detecting luminescence, fluorescence, and x-ray emissions. The introduction of concomitant x-ray imaging with bioluminescence provides an additional degree of resolution by putting the bioluminescence signal in anatomical context. Our intended use of the IVIS Lumina II XR can be separated into three general categories: 1) projects that involve CLI; 2) projects that involve BLI and fluorescence imaging for monitoring targeted radiotherapy with beta emitting radiopharmaceuticals; and 3) traditional BLI experiments. The CLI applications will focus on developing high throughput assessment of novel PET radiopharmaceuticals. Washington University has the ideal faculty and resources to more fully develop the new CLI technology. We have 8 NIH-funded users developing radiopharmaceuticals and multimodality imaging agents, and one of them (Dr. Tai) develops PET/optical instrumentation. The existing faculty, facilities and resources at WU, together with strong institutional support, will ensure that the IVIS Lumina II XR will be utilized and developed further for a new, cutting-edge technology, which will benefit WU as a university, as well as the imaging community as a whole. Public Health Relevance: Molecular imaging is a science involving non-invasive imaging of molecular processes. We propose to purchase an IVIS Lumina II XR (Caliper Life Sciences, Inc.), a new generation molecular imaging tool capable of detecting luminescence, fluorescence, and x-ray emissions. Washington University will use the instrument primarily for "Cerenkov luminescence imaging" a cutting-edge technology designed for high throughput radiopharmaceutical development.

描述（由申请人提供）：在过去的十年中，生物发光报道系统的使用已在研究应用中呈指数增长。结果，生物发光成像（BLI）已成为华盛顿大学和世界各地分子成像的不可或缺的组成部分。现在，在研究实验室中，使用多种成像方式来解决生物学问题。 Robertson等人在BLI的新转折中。 （Phys Med Biol 2009）表明，IVIS 100和200 BLI扫描仪（分别已被IVIS Lumina和Spectrum取代）可以始终检测到18F和13N核素的Cerenkov光信号。当带电的粒子以速度超过通过绝缘介质的光速行驶时，会产生Cerenkov辐射。 Cerenkov辐射是从近紫外线通过可见光谱的连续光谱产生的，与波长的岩层成反比。描述了“ Cerenkov发光成像”（CLI），用于用放射性药物散发正电子或β负的放射性药物的体内成像，并在检测皮下肿瘤植入物中与18FDG PET表现出良好的相关性。独立地，另一组研究人员（Liu等人，PLOS One 2010）用其他正电子和beta减去发射器验证了CLI。我们建议购买IVIS Lumina II XR（Caliper Life Sciences，Inc。），这是一种能够检测发光，荧光和X射线发射的新一代分子成像工具。通过将生物发光信号放置在解剖学环境中，引入具有生物发光的X射线成像具有生物发光的额外分辨率。我们对IVIS Lumina II XR的预期使用可以分为三个一般类别：1）涉及CLI的项目； 2）涉及BLI和荧光成像的项目，以通过β发出放射性药物监测靶向放射疗法； 3）传统的BLI实验。 CLI应用将着重于对新型PET放射性药物的高吞吐量评估。华盛顿大学拥有理想的教师和资源，可以更充分地开发新的CLI技术。我们有8位NIH资助的用户开发了放射性药物和多模式成像剂，其中一位（TAI博士）开发了宠物/光学仪器。 WU的现有教师，设施和资源以及强有力的机构支持将确保将IVIS Lumina II XR用于新的，尖端的技术，这将使WU作为一所大学以及整个成像社区受益。 公共卫生相关性：分子成像是一门科学，涉及分子过程的非侵入性成像。我们建议购买IVIS Lumina II XR（Caliper Life Sciences，Inc。），这是一种能够检测发光，荧光和X射线排放的新一代分子成像工具。华盛顿大学将主要用于“ Cerenkov Luminescence成像”，这是一种专为高通量放射性药物开发而设计的尖端技术。

项目成果

Cherenkov luminescence imaging of shallow sources in semitransparent media.

半透明介质中浅源的切伦科夫发光成像。

• DOI: 10.1117/1.jbo.24.2.026001
• 发表时间: 2019
• 期刊: Journal of biomedical optics
• 影响因子: 3.5
• 作者: Komarov,Sergey;Liu,Yongjian;Tai,Yuan-Chuan
• 通讯作者: Tai,Yuan-Chuan

Cherenkov luminescence imaging in transparent media and the imaging of thin or shallow sources.

透明介质中的切伦科夫发光成像以及薄或浅源的成像。

• DOI: 10.1117/1.jbo.20.3.036011
• 发表时间: 2015
• 期刊: Journal of biomedical optics
• 影响因子: 3.5
• 作者: Komarov,Sergey;Zhou,Dong;Liu,Yongjian;Tai,Yuan-Chuan
• 通讯作者: Tai,Yuan-Chuan

Activatable probes based on distance-dependent luminescence associated with Cerenkov radiation.

• DOI: 10.1002/anie.201302564
• 发表时间: 2013-07-22
• 期刊: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
• 影响因子: 16.6
• 作者: Kotagiri, Nalinikanth;Niedzwiedzki, Dariusz M.;Ohara, Kohtaro;Achilefu, Samuel
• 通讯作者: Achilefu, Samuel